POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.

Wu, Di; Jia, Hong-Yao; Wei, Na; Li, Si-Jie

Wu, Di; Jia, Hong-Yao; Wei, Na; Li, Si-Jie.

Affiliation

Wu D; Department of Breast Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Jia HY; Department of Breast Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Wei N; The First Operating Room, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Li SJ; Department of Breast Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. Electronic address: lisij@jlu.edu.cn.

Biochem Biophys Res Commun ; 533(3): 533-539, 2020 12 10.

Article in En | MEDLINE | ID: mdl-32988584

Subject(s)

Antineoplastic Agents, Immunological/therapeutic use; Breast Neoplasms/metabolism; MAP Kinase Signaling System; Transcription Factor Brn-3A/metabolism; Trastuzumab/therapeutic use; Animals; Breast Neoplasms/drug therapy; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm/genetics; Female; Humans; Mice, Nude; Mitogen-Activated Protein Kinase 1/metabolism; Mitogen-Activated Protein Kinase 3/metabolism; Neoplasm Invasiveness; Receptor, ErbB-2/analysis; Transcription Factor Brn-3A/genetics; Transcription Factor Brn-3A/physiology

Key words

Breast cancer; ERK1/2; Migration and invasion; POU4F1; Trastuzumab resistance

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / MAP Kinase Signaling System / Transcription Factor Brn-3A / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Biochem Biophys Res Commun Year: 2020 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google